World
LA NYC São Paulo London Paris Lagos Dubai Delhi Singapore Tokyo Sydney
Pulse
English · Not set Change ▾

Live scores ticker: On · Turn off

Markets ticker: On · Turn off

Saved in a cookie on this device (and in your account when you are logged in). We never store your IP address.

Entities › name

Therapeutics

277 headlines · 13 outlets · 2021-06-01 → 2026-11-19 · Wikipedia ↗ · 🔒 Follow

Latest coverage

PR Newswire: Technology ·
  • Press releases
  • Country: United States

Candel Therapeutics (CADL) Faces Investor Scrutiny After Surprise BLA Delay Drives Stock 26% Lower - Hagens Berman

SAN FRANCISCO, Nov. 19, 2026 /PRNewswire/ -- On November 13, 2026, investors in Candel Therapeutics (NASDAQ: CADL) saw the price of their shares tumble 26% on the company's announcement that it is delaying the submission of its biologics license application ("BLA") for its most advanced...

PR Newswire: Health ·
  • Press releases
  • Country: United States

Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Form New Collaboration with AstraZeneca to Advance Drug Development in Lupus

The collaboration brings together research expertise, a clinical trial network, and patient engagement NEW YORK, Nov. 19, 2026 /PRNewswire/ -- The Lupus Research Alliance (LRA) and clinical affiliate Lupus Therapeutics (LT) which oversees the Lupus Clinical Investigators Network (LuCIN)...

PR Newswire: Health ·
  • Press releases
  • Country: United States

Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026

SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the...

PR Newswire: Health ·
  • Press releases
  • Country: United States

Astrosalva Therapeutics Adds Alexander Disease Scientist Natasha Snider, PhD, to Scientific Advisory Board

UNC-Chapel Hill researcher studies GFAP, the protein whose mutations cause Alexander disease SAN MATEO, Calif., Nov. 19, 2026 /PRNewswire/ -- Astrosalva Therapeutics, Inc. ("Astrosalva"), a privately held, preclinical biotechnology company developing treatments for Alexander disease (AxD)...

Newswire.ca ·
  • Press releases
  • Country: Canada

Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026

SYDNEY, Nov. 19, 2026 /CNW/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, today announced that it has filed its Annual Report on Form 20-F for the fiscal...

PR Newswire: Technology ·
  • Press releases
  • Country: United States

Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...

PR Newswire: Health ·
  • Press releases
  • Country: United States

Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...

Newswire.ca ·
  • Press releases
  • Country: Canada

Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W schedule Disease control...

Explore

News

📈Trending💹Markets🏷️Topics🗞️Sources👤People & places⚖️Perspectives🌍Map🗓️Timeline

Daily

📋All daily lists

Banana Watch & guides

🍌Banana Originals🍌Banana Watch📺Live TV🌐Government live🏛️White House🗓️TV guide🔟Top 10 this week📱Shorts🏟️Official scores☀️Today's brief

Watch & listen

🎬Videos🍿Shows & Movies🎭Entertainment🎵Music🎙️Podcasts📻Live Radio & Scanners🏎️Games

Sports

🔴Sports Live📺Sports Watch📊Odds tracker

Local & weather

📍Near you🌦️Weather & radar🏳️Countries

Understand & explore

🧩Same story🔁What changed🏁Who's first🌐Web trends❓Why it's trending🔗Compare an article📜On this day⏳Time Machine🐇Rabbit hole📰Front page📚Free books🧠Daily quiz🔮Forecasts (play money)

Join

🔑Log in🍌Sign up 📲Notifications🍌Calm mode✉️Email briefing📦Offline pack

Banana News

⭐Pricing🍌Banana Coin✍️Creatorsℹ️About🛍️Shop

Banana News Single Banana

Upgrade to unlock this

See plans Log in

Free accounts get fresh bananas every day. Cancel anytime · pay by card or USDC on Base · compare all plans

↑↓ move · ↵ go · ? shortcuts

Keyboard shortcuts

Move

j / k next / previous story

o or ↵ open original

d story details

b bookmark

Go

g h home · g f front page

g t timeline · g y time machine

g b briefing · g p perspectives

g m map · g o on this day

g r rabbit hole · g w wrapped

Everywhere

/ search

Ctrl/⌘ K command palette

t cycle theme

? this help · Esc close

Shortcuts never fire while you are typing, and are off when you hold Ctrl, Alt or ⌘.

Ask Ara

Ara answers only from Banana News. Your voice stays in your browser; nothing is saved.

What each plan gets here

Every plan (Single Banana, Bunch, Crate, Banana Tree): Everything - voice, all 15 languages (Ara's own voice where it's ready, text otherwise - never a robot voice), know-how. Ara is free for everyone.

Compare plans